Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies.
Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer treatment and its incidence is growing. It significantly affects quality of life and is a dose-limiting factor that interferes with treatment. Its diagnosis can be established in clinical terms but some complementary tests can help when the diagnosis is difficult. There is still no proven method to prevent it that has become a standard of care in spite of the huge amount of investigation carried out in recent years. There are promising strategies that could help reduce the burden of this complication. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.
Gutiérrez-Gutiérrez
Gerardo
G
Neurology Department, Infanta Sofía Hospital, San Sebastián de los Reyes, Madrid, Spain.
Sereno
María
M
Miralles
Ambrosio
A
Casado-Sáenz
Enrique
E
Gutiérrez-Rivas
Eduardo
E
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D019587:Dietary Supplements; D006801:Humans; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000627:therapeutic use; D017933:Peripheral Nervous System / Q000187:drug effects / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D017671:Platinum Compounds / Q000009:adverse effects / Q000494:pharmacology; D014815:Vitamins / Q000627:therapeutic use
D018696:Neuroprotective Agents; D017671:Platinum Compounds; D014815:Vitamins